Dexcom (DXCM) Cash & Current Investments (2010 - 2026)

Dexcom (DXCM) has 17 years of Cash & Current Investments data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 58.61% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 58.61% decrease from a year earlier, with the FY2025 full-year figure at $917.7 million, down 56.46% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $1.1 billion, up from $917.7 million in the prior quarter.
• Over the last five years, Cash & Current Investments for DXCM reached as high as $3.6 billion in Q2 2023 and fell as low as $917.7 million in Q4 2025.
• Historically, Cash & Current Investments has averaged $2.4 billion across 5 years, with a median of $2.6 billion in 2023.
• Across the five-year window, Cash & Current Investments surged 36.61% in 2023 and tumbled 62.86% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $2.5 billion in 2022, then increased by 10.91% to $2.7 billion in 2023, then dropped by 22.63% to $2.1 billion in 2024, then slumped by 56.46% to $917.7 million in 2025, then advanced by 21.85% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $1.1 billion in Q1 2026, $917.7 million in Q4 2025, and $1.4 billion in Q3 2025.